The Molecular Pathogenesis of Osteosarcoma: A Review

Sarcoma · 2011 · Classic · cited 350 times

Matthew L. Broadhead, Jonathan C. M. Clark, Damian E. Myers, Crispin R. Dass, Peter Choong

Orthopaedic Oncology Pediatric Orthopaedics

SUMMARY — THE REDUCTIONThis 2011 review outlines the molecular pathogenesis of osteosarcoma and emerging translational research aimed at identifying targeted therapies to improve outcomes beyond current anatomically based staging and treatment.
Abstract, as published

Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%-70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational studies performed to date in search of novel, safer, and more targeted drugs for disease management.

Featured in the 2026-09-19 issue.

← Strategies for Pediatric Diaphyseal Bone Reconstruction of th…Tumors of the Hand and the Wrist. →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.